Abstract：
BACKGROUND: Aidi injection is one of the China Food and Drug Administration approved Chinese herbal injections and the most competitive product in cancer care in China. It is composed of the extracts from Mylabris Phalerata, Astragalus Membranaceus, Panax Ginseng, and Acanthopanax Senticosus.
OBJECTIVE: This overview aims to map systematic reviews (SRs) of Aidi injection for cancer and provide a summarized evidence for clinical practice and decision making.
METHODS: Seven databases were searched for SRs and/or meta-analyses of randomized controlled trials on Aidi injection for cancer care until December 2020. Six authors worked in pairs independently identified studies, collected data, and assessed the quality of included studies according to the revised Assessment of Multiple Systematic Reviews (AMSTAR 2) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A narrative synthesis was used for the evidence mapping.
RESULTS: Fifty-two SRs on Aidi injection as adjuvant therapy were included, involving lung cancer (20 SRs), liver cancer (10), colorectal cancer (7), gastric cancer (6), lymphoma (2), breast cancer (2), esophageal cancer (1), ovary cancer (1), and a mix of different cancers (4). Except for one SR focusing on Aidi injection used alone, other SRs evaluated Aidi injection in combination with chemotherapy (43), radiotherapy (4), or chemo/radiology/targeting therapy (4). Aidi injection showed additional beneficial effects on survival (9), objective response rate (44), quality of life (42), and the reduction of side-effects from chemo/radiotherapy (48). Using AMSTAR 2 tool, two reviews were assessed as low and the rest as critically low methodological quality mainly due to the lack of prospective registration. The reporting quality was insufficient assessed with PRISMA in the reporting of search strategy (26, 50.0%), additional analysis (19, 36.5%), and the summary of evidence (2, 3.8%).
CONCLUSIONS: Aidi injection has been evaluated for its adjuvant beneficial effects on cancer survival, tumor responses, quality of life, and reducing the side effects of chemo/radiotherapy, mainly focusing on lung, liver and colorectal cancer. The methodological and reporting quality are weak and need to be improved in the future.
OBJECTIVE: This overview aims to map systematic reviews (SRs) of Aidi injection for cancer and provide a summarized evidence for clinical practice and decision making.
METHODS: Seven databases were searched for SRs and/or meta-analyses of randomized controlled trials on Aidi injection for cancer care until December 2020. Six authors worked in pairs independently identified studies, collected data, and assessed the quality of included studies according to the revised Assessment of Multiple Systematic Reviews (AMSTAR 2) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A narrative synthesis was used for the evidence mapping.
RESULTS: Fifty-two SRs on Aidi injection as adjuvant therapy were included, involving lung cancer (20 SRs), liver cancer (10), colorectal cancer (7), gastric cancer (6), lymphoma (2), breast cancer (2), esophageal cancer (1), ovary cancer (1), and a mix of different cancers (4). Except for one SR focusing on Aidi injection used alone, other SRs evaluated Aidi injection in combination with chemotherapy (43), radiotherapy (4), or chemo/radiology/targeting therapy (4). Aidi injection showed additional beneficial effects on survival (9), objective response rate (44), quality of life (42), and the reduction of side-effects from chemo/radiotherapy (48). Using AMSTAR 2 tool, two reviews were assessed as low and the rest as critically low methodological quality mainly due to the lack of prospective registration. The reporting quality was insufficient assessed with PRISMA in the reporting of search strategy (26, 50.0%), additional analysis (19, 36.5%), and the summary of evidence (2, 3.8%).
CONCLUSIONS: Aidi injection has been evaluated for its adjuvant beneficial effects on cancer survival, tumor responses, quality of life, and reducing the side effects of chemo/radiotherapy, mainly focusing on lung, liver and colorectal cancer. The methodological and reporting quality are weak and need to be improved in the future.
摘要：
背景：艾迪注射液是中国食品药品监督管理局批准的中药注射剂之一，也是中国癌症治疗领域最具竞争力的产品。它由MylabrisPhalerata的提取物组成，黄芪，人参,和刺五加。
目的：本概述旨在绘制艾迪注射液治疗癌症的系统评价（SRs）图，为临床实践和决策提供总结证据。
方法：直到2020年12月，在七个数据库中搜索关于艾迪注射液用于癌症治疗的随机对照试验的SR和/或荟萃分析。六名作者成对独立确定的研究，收集的数据,并根据修订后的《多重系统评价》(AMSTAR2)和系统评价和荟萃分析首选报告项目(PRISMA)评估纳入研究的质量。叙事综合用于证据映射。
结果：纳入艾迪注射液辅助治疗的52个SRs，涉及肺癌（20SR），肝癌（10），大肠癌（7），胃癌（6），淋巴瘤（2），乳腺癌(2),食管癌(1)，卵巢癌（1），和不同癌症的混合（4）。除了一个专注于艾迪注射液的SR单独使用，其他SR评估了艾迪注射液与化疗的联合(43)，放射治疗（4），或化学/放射学/靶向治疗（4）。艾迪注射液对存活显示出额外的有益作用(9)，客观反应率（44），生活质量（42）和减少化疗/放疗的副作用（48）。使用AMSTAR2工具，两项审查被评估为低,其余评价为方法质量严重不足,主要是由于缺乏前瞻性注册.在搜索策略的报告中，PRISMA评估的报告质量不足(26，50.0%)，附加分析（19，36.5%），和证据摘要（2，3.8％）。
结论：已经评估了艾迪注射液对癌症生存的辅助有益作用，肿瘤反应，生活质量,减少化疗/放疗的副作用，主要集中在肺，肝癌和结直肠癌。方法和报告质量薄弱，今后需要改进。
目的：本概述旨在绘制艾迪注射液治疗癌症的系统评价（SRs）图，为临床实践和决策提供总结证据。
方法：直到2020年12月，在七个数据库中搜索关于艾迪注射液用于癌症治疗的随机对照试验的SR和/或荟萃分析。六名作者成对独立确定的研究，收集的数据,并根据修订后的《多重系统评价》(AMSTAR2)和系统评价和荟萃分析首选报告项目(PRISMA)评估纳入研究的质量。叙事综合用于证据映射。
结果：纳入艾迪注射液辅助治疗的52个SRs，涉及肺癌（20SR），肝癌（10），大肠癌（7），胃癌（6），淋巴瘤（2），乳腺癌(2),食管癌(1)，卵巢癌（1），和不同癌症的混合（4）。除了一个专注于艾迪注射液的SR单独使用，其他SR评估了艾迪注射液与化疗的联合(43)，放射治疗（4），或化学/放射学/靶向治疗（4）。艾迪注射液对存活显示出额外的有益作用(9)，客观反应率（44），生活质量（42）和减少化疗/放疗的副作用（48）。使用AMSTAR2工具，两项审查被评估为低,其余评价为方法质量严重不足,主要是由于缺乏前瞻性注册.在搜索策略的报告中，PRISMA评估的报告质量不足(26，50.0%)，附加分析（19，36.5%），和证据摘要（2，3.8％）。
结论：已经评估了艾迪注射液对癌症生存的辅助有益作用，肿瘤反应，生活质量,减少化疗/放疗的副作用，主要集中在肺，肝癌和结直肠癌。方法和报告质量薄弱，今后需要改进。
